CYP3A5 phenotype-genotype correlations in a British population

British Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2003, Pages 625-629

  King, Barry P ^a   Leathart, Julian B S ^a   Mutch, Elaine ^a   Williams, Faith M ^a   Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

CYP3A5; Cytochrome P450; Human liver; PCR assay; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 3A5; DNA;

ADULT; AGED; ARTICLE; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 ENZYME SYSTEM; DNA; GENOTYPE; HETEROZYGOTE; HUMANS; MICROSOMES, LIVER; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0038713368     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01798.x     Document Type: Article

References (24)

1. Guengerich FP. Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
2. Gellner K, Eiselt R, Hustert E et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11: 111-121.
3. Aoyama T, Yamano S, Waxman DJ et al. Cytochrome P450 hPCN3, a novel cytochrome P450 IIIa gene product that is differentially expressed in adult human liver. J Biol Chem 1989; 264: 10388-10395.
4. Wrighton SA, Brian WR, Sari MA et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (Hlp3). Mol Pharmacol 1990; 38: 207-213.
5. Kuehl P, Zhang J, Lin Y et al. Sequence diversity, in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001; 27: 383-391.
6. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
7. http://www.imm.ki.se/CYPalleles/
8. Gillam EMJ, Guo Z, Ueng Y-F et al. Expression of cytochrome P450 3A5 in Escherichia toli: effects of 5′modification, purification, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 1995; 317: 374-384.
9. Williams JA, King BJ, Cantrell VE et al. Comparative metabolic capabilities of CYP3A4, CYP3A5 and CYP3A7. Drug Metab Dispos 2002; 30: 883-891.
10. Santos A, Zanetta S, Cresteil T et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6: 2012-2020.
11. Nielsen TL, Rasmussen BB, Flinois Jp, Beaune P, Brosen K. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 1999; 289: 31-37.
12. Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 2000; 58: 1341-1348.
13. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol 1996; 272: 199-210.
14. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucl Acids Res 1976; 3: 2303-2308.
15. Mutch E, Blain PG, Williams FM. The role of metabolism in determining susceptibility to parathion toxicity in man. Toxicol Lett 1999; 107: 177-187.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T7. Nature 1970; 227: 680-685.
17. Lin YS, Dowling ALS, Quigley SD et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-172.
18. Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug adnfinistration method. Pharmacogenetics 2000; 10: 373-388.
19. Goodwin B, Redinbo MR, Kliewer SA. Regulation of CYP3A gene transcription by the pregnane X receptor. Ann Rev Pharmacol Toxicol 2002; 42: 1-23.
20. Dai D, Tang J, Rose R et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 299: 825-831.
21. Lamba JK, Lin YS, Thummel K et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121-132.
22. Zhang J, Kuehl P, Green ED et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11: 555-572.
23. Hustert E, Zibat A, Presecan-Siedel E et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001; 29: 1454-1459.
24. Westlind A, Malmebo S, Johansson I et al. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281: 1349-1355.